Call Us: 1.800.873.5297

By

Ingredient in Colgate Total Toothpaste Linked to Cancer, Bloomberg Reports

Bloomberg reports that an active ingredient in Colgate Total toothpaste, Triclosan, is linked to cancer-cell growth and disrupted development in animals. Although many companies have stopped using this antibacterial chemical in their products, Colgate stands by its use of Triclosan citing the FDA’s approval of its product as an over-the-counter drug in 1997. However, Bloomberg […]

By

FDA Warns of Dangerous Testosterone Risks for Men, NBC News Reports

NBC Nightly News reports that “[t]estosterone treatment is a growing multibillion-dollar business, but it presents the risk of life-threatening blood clots.” In the news segment, the NBC reporter comments: “In 2013, doctors wrote 7.5 million prescriptions for testosterone, up from about 4 million in 2009. While treatment for abnormally low testosterone levels is warranted in […]

By

Pradaxa® MDL 2385 Update: Court Orders Establishment of Qualified Settlement Fund

The Honorable Judge David Herndon, who is overseeing the Pradaxa® Multidistrict Litigation, has ordered the establishment of a “qualified settlement fund” and appointed an administrator of the settlement fund. (CMO 82, In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, Case No. 12-md-2385, S.D. Ill.) Now that a qualified settlement fund has been established and an […]

By

TVM Lawsuit Update: Second Trial Against Boston Scientific Begins in Massachusetts

On August 14, the second bellwether trial against Boston Scientific began in the Massachusetts state court consolidated litigation. The trial involves allegations by plaintiff Maria Cardenas that the Boston Scientific transvaginal mesh (TVM) product she was implanted with caused her serious injuries. (Cardenas v. Boston Scientific Corp., Case No. 12-02912, Superior Court of the Commonwealth […]

By

Xarelto® Lawsuit Update: New Study Finds Bleeding Difficult to Stop for Some Anticoagulants, Including Xarelto®

A new study published in the August issue of the Journal of Neurosurgery found that internal bleeding associated with certain anticoagulants – including Xarelto® – is more difficult to stop in comparison to other blood thinning medications. The study discussed new guidelines on how to treat uncontrolled bleeding in the brain and pointed out that […]

By

Transvaginal Mesh Lawsuit Update: FDA Rejects Public Citizen’s Petition to Ban and Recall TVM Devices

The U.S. Food and Drug Administration (FDA) has issued its Final Response rejecting a 2011 Petition Filed by Public Citizen, a non-profit consumer advocacy organization, calling for a total ban and complete recall  of the Transvaginal Mesh® (TVM) devices used for the treatment of pelvic organ prolapse (POP). Public Citizen also petitioned the FDA to […]

By

Experts Question Strength of Data in Actos® Alzheimer’s Study

Experts are questioning the strength of data in a new study demonstrating that a diabetes medication created a slight decrease in the risk of a person developing Alzheimer’s. As part of the recent study, researchers followed 145,717 people ages 60 or older who were taking the diabetes medicine Actos® (pioglitazone) and who were also part […]

By

FDA Approves New Drug for Type 2 Diabetes: Jardiance®

The U.S. Food and Drug Administration (FDA) has approved the diabetes drug Jardiance® (empagliflozin) to improve glycemic control in adults with type 2 diabetes. The FDA states that the Jardiance® tablets should be used in addition to diet and exercise to control type 2 diabetes. Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug […]

By

$2.1 Million Jury Verdict Reversed in Accutane® Lawsuit

The Switzerland-based manufacturer, Roche Holding AG, recently won a reversal of a $2.1 million jury verdict in favor of a California woman who alleged the company’s Accutane® acne medication caused her inflammatory bowel disease (IBD), Bloomberg reports. Plaintiff Gillian Gaghan’s case went to trial in 2011, where she alleged that the company failed to warn […]

By

First Trial in DePuy Pinnacle™ MDL Set to Begin In September

The first bellwether trial in the DePuy Pinnacle™ Multidistrict Litigation (In Re: DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litigation, Case No. 3:11-md-02244, MDL No. 2244) will begin on September 1, 2014, as set forth in Case Management Order No. 8. The first trial involves cases filed by two plaintiffs: Kathleen Herlihy-Paoli and Toni […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.